Key Points
- CEO Roger Susi sold 2,500 shares on April 14 at an average price of $93.84 for roughly $234,600 under a pre‑arranged Rule 10b5‑1 plan, leaving him with 2,210,000 shares (a 0.11% ownership decrease).
- Operational and shareholder updates: iRadimed beat Q results (EPS $0.54 vs. $0.49; revenue $22.69M vs. $21.60M), provided Q1 2026 guidance of 0.440–0.480 EPS and FY2026 guidance of 2.060–2.210 EPS, and raised its quarterly dividend to $0.20 (annualized $0.80, ~0.9% yield); analysts' consensus rating is "Buy" with a $120 price target.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of the firm's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $93.84, for a total transaction of $234,600.00. Following the completion of the transaction, the chief executive officer directly owned 2,210,000 shares in the company, valued at approximately $207,386,400. This represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Trading Down 0.5%
NASDAQ:IRMD opened at $93.05 on Thursday. The company's 50-day moving average price is $99.11 and its 200-day moving average price is $92.76. The company has a market cap of $1.19 billion, a P/E ratio of 53.17 and a beta of 1.11. iRadimed Corporation has a twelve month low of $50.00 and a twelve month high of $107.90.
iRadimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The firm had revenue of $22.69 million during the quarter, compared to analysts' expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.
iRadimed Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a dividend of $0.20 per share. The ex-dividend date was Monday, February 23rd. This is an increase from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed's dividend payout ratio (DPR) is 45.71%.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on IRMD. Lake Street Capital reiterated a "buy" rating and set a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Roth Mkm reiterated a "buy" rating and set a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Freedom Capital upgraded shares of iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. Finally, Weiss Ratings reiterated a "buy (b-)" rating on shares of iRadimed in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $120.00.
Get Our Latest Stock Report on IRMD
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in IRMD. Royal Bank of Canada grew its holdings in shares of iRadimed by 14.7% in the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock valued at $1,354,000 after purchasing an additional 3,307 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of iRadimed by 7.5% in the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock valued at $831,000 after purchasing an additional 1,108 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after purchasing an additional 234 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of iRadimed by 8,568.5% in the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock valued at $591,000 after purchasing an additional 11,139 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock valued at $8,889,000 after purchasing an additional 1,821 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company's stock.
About iRadimed
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
